United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

23 Sep 2016
Change (% chg)

kr.-1.00 (-0.38%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Tue, Sep 13 2016

BRIEF-Bavarian Nordic: Janssen completes submission for EUAL for Ebola vaccine regimen to WHO

* Said on Monday its partner, Janssen had completed submission for Emergency Use Assessment and Listing (EUAL) for its Ebola vaccine regimen to World Health Organization

BRIEF-Bavarian Nordic Q2 EBIT swings to loss DKK 54.0 million

* H1 revenue 139 million Danish crowns ($21 million) versus 624 million crowns year ago

BRIEF-Bavarian Nordic starts Phase 1 trial of MVA-BN-based Yellow Fever Vaccine

* Announced initiation of a Phase 1 clinical trial of MVA-BN-based Yellow Fever Vaccine

BRIEF-Bavarian Nordic: Expansion of IMVAMUNE orders from Canada

* Announces expansion of IMVAMUNE orders from Canadian government

BRIEF-Bavarian Nordic: Positive results from Phase 1 Trial of broad spectrum RSV vaccine

* Announces positive top line results from a Phase 1 Trial of a novel, broad spectrum RSV vaccine in healthy adult and elderly populations

BRIEF-Bavarian Nordic signs $100 million contract for IMVAMUNE in USA

* Announces $100 million supply contract for IMVAMUNE Smallpox Vaccine with the U.S. Government

BRIEF-Bavarian Nordic Q1 EBIT loss increases to DKK 153 million

* Q1 revenue 23 million Danish crowns ($3.52 million) versus 235 million crowns year ago

BRIEF-Bavarian Nordic: Positive data for Ebola vaccine regimen

* Said on Tuesday results of Phase 1 study of a preventive Ebola vaccine regimen suggest that regimen was well-tolerated by healthy volunteers and did not result in any vaccine-related serious adverse events

CORRECTED-BRIEF-Bavarian Nordic to raise up to DKK 665 mln in private placement

* Said on Wednesday resolved to launch an offering of up to 2.8 million shares

Select another date: